A Study To See Why Patients Agree To or Decline To Have Treatment After Surgery

Why Do Patients Agree To or Decline Adjuvant Immunotherapy and Are They Satisfied With Their Decision?

The purpose of this study is to find out what patients consider when deciding whether or not to receive adjuvant treatment, and how patients feel about their decision after one year.

Inclusion Criteria:

• Patients with stage IIIB, IIIC, IIID, or IV (AJCC, 8th edition) cutaneous melanoma rendered free of disease by surgical resection.
• Patients are being offered adjuvant nivolumab or pembrolizumab therapy
• Patient has not yet formally discussed their treatment options with their Medical Oncologist.
• Age 18 or older.
• Ability to speak and read English because we do not have the resources to translate materials into other languages.

Exclusion Criteria:

• Patient not currently free of disease.
• Candidate for adjuvant dabrafenib/trametinib therapy.
• Patients who have received prior checkpoint inhibitor therapy.